Fund managers have forecast an M&A boom for the biotech sector following Donald Trump's win in the US Presidential Election, but have warned of future uncertainty for wider healthcare services companies in areas such as Obamacare.
In the 24 hours following the US election result, healthcare and biotech-focused investment trusts rebounded after facing significant headwinds in the run-up to the vote, as the Nasdaq Biotechnology index...
Kaynor assumes role
Latest news and analysis
Moves to overweight equities and fixed income
Industry Voice Sponsored by T.Rowe Price: With market volatility likely to persist and the US dollar potentially near a peak, prudent investors may want to position their portfolios to take advantage of assets that have historically performed well late...
The Big Interview: Focus on ethical investment